NDAORALTABLET
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEPADIN (bepridil hydrochloride) is an oral calcium channel blocker approved in 1990 for cardiovascular indications. The mechanism of action involves modulation of calcium influx to reduce cardiac workload and improve coronary blood flow. It is a small molecule therapeutic indicated for angina management.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating smaller team size and focus on retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BEPADIN offers limited career growth opportunities due to its LOE-approaching lifecycle stage and zero linked job openings. Roles available are primarily focused on defending market share and managing transition to generic competition rather than launching new initiatives.
Brand ManagerField Sales Representative
Worked on BEPADIN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.